Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

S. G.P. Funnell; W. E. Dowling; C. Muñoz-Fontela; P. S. Gsell; D. E. Ingber; G. A. Hamilton; L. Delang; J. Rocha-Pereira; S. Kaptein; K. H. Dallmeier; J. Neyts; K. Rosenke; E. de Wit; H. Feldmann; P. Maisonnasse; R. Le Grand; M. B. Frieman; C. M. Coleman

doi:10.1038/s41467-020-17907-w

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

S. G.P. Funnell, W. E. Dowling, C. Muñoz-Fontela, P. S. Gsell, D. E. Ingber, G. A. Hamilton, L. Delang, J. Rocha-Pereira, S. Kaptein, K. H. Dallmeier, J. Neyts, K. Rosenke, E. de Wit, H. Feldmann, P. Maisonnasse, R. Le Grand, M. B. Frieman, C. M. Coleman

Research output: Contribution to journal › Comment/debate

39 Scopus citations

Original language	English
Article number	4253
Journal	Nature Communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-17907-w
State	Published - 1 Dec 2020
Externally published	Yes

Access to Document

10.1038/s41467-020-17907-w

Cite this

Funnell, S. G. P., Dowling, W. E., Muñoz-Fontela, C., Gsell, P. S., Ingber, D. E., Hamilton, G. A., Delang, L., Rocha-Pereira, J., Kaptein, S., Dallmeier, K. H., Neyts, J., Rosenke, K., de Wit, E., Feldmann, H., Maisonnasse, P., Le Grand, R., Frieman, M. B., & Coleman, C. M. (2020). Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nature Communications, 11(1), Article 4253. https://doi.org/10.1038/s41467-020-17907-w

@article{c844b033b0544892b8648a00ce7b2c16,

title = "Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients",

author = "Funnell, {S. G.P.} and Dowling, {W. E.} and C. Mu{\~n}oz-Fontela and Gsell, {P. S.} and Ingber, {D. E.} and Hamilton, {G. A.} and L. Delang and J. Rocha-Pereira and S. Kaptein and Dallmeier, {K. H.} and J. Neyts and K. Rosenke and {de Wit}, E. and H. Feldmann and P. Maisonnasse and {Le Grand}, R. and Frieman, {M. B.} and Coleman, {C. M.}",

note = "Funding Information: D.E. Ingber acknowledges research funding from NIH NCATS UH3-HL-141797 and DARPA under Cooperative Agreements HR00111920008 and HR0011-20-2-0040. P. Maisonnass acknowledges financial support from REACTing, the National Research Agency (ANR-AM-CoV-Path), the European Union{\textquoteright}s Horizon 2020 (H2020) research and innovation programme Fight-nCov (grant No. 101003555), the European Union IMI2 programme CARE (grant No. 101005077), the European Infrastructure TRANS-VAC2 (grant No. 730964) and virus stock was obtained through the EVAg platform (https://www.european-virus-archive.com/) funded by H2020 (Grant No. 653316). The Inserm Infectious Disease Models and Innovative Therapies research infrastructure (IDMIT) is supported by the “Programme Investissements d{\textquoteright}Avenir” (PIA), managed by the ANR under reference ANR-11-INBS-0008, the Fondation Bettencourt Schueller, the Region Ile-de-France and the Domaine d{\textquoteright}Int{\'e}r{\^e}t Majeur (DIM, Paris, France) “One Health”. H. Feldmann acknowledges that the Laboratory of Virology was funded by the NIAID Intramural Research Programme",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-17907-w",

language = "English",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Funnell, SGP, Dowling, WE, Muñoz-Fontela, C, Gsell, PS, Ingber, DE, Hamilton, GA, Delang, L, Rocha-Pereira, J, Kaptein, S, Dallmeier, KH, Neyts, J, Rosenke, K, de Wit, E, Feldmann, H, Maisonnasse, P, Le Grand, R, Frieman, MB & Coleman, CM 2020, 'Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients', Nature Communications, vol. 11, no. 1, 4253. https://doi.org/10.1038/s41467-020-17907-w

TY - JOUR

T1 - Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

AU - Funnell, S. G.P.

AU - Dowling, W. E.

AU - Muñoz-Fontela, C.

AU - Gsell, P. S.

AU - Ingber, D. E.

AU - Hamilton, G. A.

AU - Delang, L.

AU - Rocha-Pereira, J.

AU - Kaptein, S.

AU - Dallmeier, K. H.

AU - Neyts, J.

AU - Rosenke, K.

AU - de Wit, E.

AU - Feldmann, H.

AU - Maisonnasse, P.

AU - Le Grand, R.

AU - Frieman, M. B.

AU - Coleman, C. M.

N1 - Funding Information: D.E. Ingber acknowledges research funding from NIH NCATS UH3-HL-141797 and DARPA under Cooperative Agreements HR00111920008 and HR0011-20-2-0040. P. Maisonnass acknowledges financial support from REACTing, the National Research Agency (ANR-AM-CoV-Path), the European Union’s Horizon 2020 (H2020) research and innovation programme Fight-nCov (grant No. 101003555), the European Union IMI2 programme CARE (grant No. 101005077), the European Infrastructure TRANS-VAC2 (grant No. 730964) and virus stock was obtained through the EVAg platform (https://www.european-virus-archive.com/) funded by H2020 (Grant No. 653316). The Inserm Infectious Disease Models and Innovative Therapies research infrastructure (IDMIT) is supported by the “Programme Investissements d’Avenir” (PIA), managed by the ANR under reference ANR-11-INBS-0008, the Fondation Bettencourt Schueller, the Region Ile-de-France and the Domaine d’Intérêt Majeur (DIM, Paris, France) “One Health”. H. Feldmann acknowledges that the Laboratory of Virology was funded by the NIAID Intramural Research Programme

PY - 2020/12/1

Y1 - 2020/12/1

UR - http://www.scopus.com/inward/record.url?scp=85089895635&partnerID=8YFLogxK

U2 - 10.1038/s41467-020-17907-w

DO - 10.1038/s41467-020-17907-w

M3 - Comment/debate

C2 - 32848158

AN - SCOPUS:85089895635

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 4253

ER -